Advertisement: TTP Killer 50
19 February, 2022 - 16:15 By Tony Quested

Eliem Therapeutics

Eliem Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.

In May 2021 Eliem raised a $60 million Series B to take its fundraising haul to $140m. The company then raised $92m through an oversubscribed NASDAQ IPO in August 2021.

Job opportunities at Eliem Therapeutics

 

Newsletter Subscription

Stay informed of the latest news and features